Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases.
Control of experimental autoimmune uveoretinitis by low dose T cell vaccination.
Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.
The value of specialty pharmaceuticals - a systematic review.
Sodium channels contribute to microglia/macrophage activation and function in EAE and MS.
Incidence of multiple sclerosis in the United Kingdom : findings from a population-based cohort.
Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis.
Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.
The Brief Repeatable Battery: psychometrics and normative values with age, education and gender corrections in a Serbian population.
English Court of Appeal finds in favor of Teva on Copaxone(R) patent litigation and upholds validity of Copaxone patent until May 2015
Combining HLA-DR risk alleles and anti-Epstein-Barr virus antibody profiles to stratify multiple sclerosis risk.
iPSC-derived neural precursors exert a neuroprotective role in immune-mediated demyelination via the secretion of LIF.
Stress and the risk of multiple sclerosis.
Severe anemia in a patient with multiple sclerosis treated with natalizumab.
Increased PK11195 PET binding in the cortex of patients with MS correlates with disability.
Shorter washout reduces MS relapse switching off natalizumab
The antioxidant idebenone fails to prevent or attenuate chronic experimental autoimmune encephalomyelitis in the mouse.
Acute Cryptococcal Immune Reconstitution Inflammatory Syndrome in a Patient on Natalizumab.
Opposite Roles of NMDA Receptors in Relapsing and Primary Progressive Multiple Sclerosis.
Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials.
[Infections and fingolimod].
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Biogen Idec announces positive top-line results from Phase 3 study of peginterferon beta-1a in multiple sclerosis
Co-enzyme Q10 and idebenone use in Friedreich's ataxia.
SIRT1 deacetylates RORγt and enhances Th17 cell generation.

Pages